ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer and Monogram Biosciences have formed a nonexclusive collaboration under which the firms will make Monogram's HIV Co-Receptor Tropism Assay—a diagnostic tool to show the path taken by the virus to access human CD4 cells—available to patients worldwide. As part of the agreement, Pfizer will invest $25 million in Monogram. Tropism information is intended to help identify patients most likely to respond to a new class of investigational drugs called CCR5 antagonists. Pfizer currently has a CCR5 candidate, maraviroc, in Phase III clinical trials and uses Monogram's tropism assay to select patients for enrollment in late-stage clinical studies.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X